Tryp Therapeutics Inc (TRYPF) Corporate Presentation

Corporate Presentation Fall 2021 THE HIGH PREVALENCE OF OUR TARGET INDICATIONS CREATES A COMPELLING MARKET OPPORTUNITY Diagnosed Prevalence in the U.S. Peak Annual Worldwide Sales Potential for Tryp 28 Tryp is pursuing chronic pain and other indications to address the significant needs of patients. Because of the relatively high prevalence of these diseases, the market opportunity for the successful development and commercialization of our treatments is more than $12 billion in annual sales. Figures based on internal analysis by Tryp Therapeutics. Details of prevalence assumptions available upon request.